The buyer here trained at one of three research universities
Three major research universities sit inside one small triangle, feeding a dense cluster of contract research organizations and life-sciences vendors. The buyer on the other end of your campaign is often a working scientist, not a marketing-literate procurement generalist.
Benchmarks in this market
- Pipeline closed, technical B2B
- $8.4MPipeline closed, technical B2B
- Pipeline value, specification-led content
- +312%Pipeline value, specification-led content
- Target account engagement
- 34%Target account engagement
- Sales cycle length, ABM
- -29%Sales cycle length, ABM
How we work here: Remotely from our San Francisco office, with ET coverage for calls and travel for kickoffs. We don't claim a Raleigh-Durham office we don't have.
Clients across every market
What's actually different about the Research Triangle
The Research Triangle's defining economic fact is the cluster of contract research organizations (CROs) — companies that run clinical trials and lab research on behalf of pharmaceutical and biotech companies — anchored by Research Triangle Park and fed directly by Duke, UNC-Chapel Hill, and NC State producing a genuinely dense pipeline of life-sciences and technical talent inside one metro. That's a structurally different buyer from Boston's biotech cluster, which centers on hospital systems and biotech company headquarters themselves. RTP's buyer is more often the vendor selling services *into* those companies — a CRO's business-development lead, a lab-equipment or clinical-software vendor, a specialty logistics provider for temperature-sensitive shipments. The pitch has to survive scrutiny from people with a genuine science background, not just a procurement checklist.
CRO buyers evaluate scientific credibility first
A CRO or lab-services vendor's marketing content gets read by people with graduate-level science training who can spot an inaccurate methodology claim in one sentence. Content that would pass in a general B2B market gets discounted immediately here if it gets the science loosely right rather than precisely right.
The talent pipeline is the actual local advantage to sell against
Three R1 research universities producing a steady flow of PhDs and technical graduates is a genuine, durable local advantage for companies here — but most RTP companies market their services without ever mentioning the talent depth behind them, which is frequently the more persuasive argument to a buyer weighing a vendor relationship.
Regulatory and compliance vocabulary is the actual language of the sale
GLP, GCP, FDA submission pathways, and IRB processes aren't jargon to soften for a general audience here — they're the specific terms a technical buyer uses to evaluate whether a vendor actually understands their world, and avoiding them reads as inexperience, not accessibility.
Lower cost base than Boston, without a talent-quality discount
RTP offers a materially lower cost of living and operating cost than Boston's biotech corridor while drawing from the same caliber of research talent, which is a real structural advantage for companies choosing where to build — and one most RTP companies undersell in their own positioning.
What usually moves first in Raleigh-Durham.
Based on what tends to be the binding constraint for companies in this market. Your audit may point somewhere else — we go where the numbers say.
Industry playbooks relevant in Raleigh-Durham
The part clients actually remember.
Not the reports. The uncomfortable conversation that changed the trajectory.
The hardest part was telling the board our old reporting had been optimistic, and that we would now be running fewer tests and winning less often. Watching the conversion rate move for the first time in two years made that conversation retrospectively easy.
We had spent four years measuring the content team on how much they published, and then wondering why none of it ranked. Deleting two hundred and fifty pages was the most uncomfortable thing we have done and the most obviously correct in hindsight.
We spent a year proud of our lead numbers while our close rate quietly fell apart, and nobody thought to ask whether we could actually service what we were buying. Cutting lead volume on purpose felt insane until the crew-week numbers came in.
Raleigh-Durham questions, answered straight.
We assign writers with relevant life-sciences or clinical-research backgrounds and run structured interviews with your scientific team, and your team reviews every methodology or regulatory claim before it ships. Content that gets GLP, GCP, or a trial-phase detail wrong is worse than no content at all with this buyer — they notice immediately and it costs credibility you don't get back.
Other markets we work in
Let's look at your numbers.
A free 30-minute teardown of your funnel, ads, and site — run against what actually works in the Research Triangle. You keep the findings either way.